cp 100356 has been researched along with dofequidar in 1 studies
Studies (cp 100356) | Trials (cp 100356) | Recent Studies (post-2010) (cp 100356) | Studies (dofequidar) | Trials (dofequidar) | Recent Studies (post-2010) (dofequidar) |
---|---|---|---|---|---|
8 | 0 | 3 | 40 | 2 | 5 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Guengerich, P; Kajiji, S; Kim, RB; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
1 other study(ies) available for cp 100356 and dofequidar
Article | Year |
---|---|
P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
Topics: Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Digoxin; Down-Regulation; Enzyme Inhibitors; Humans; Oxidoreductases, N-Demethylating; Substrate Specificity | 1999 |